Category: MSA, PSP, CBS: Neuroimaging
Objective: This study aimed to evaluate the diagnostic utility of florzolotau (18F) positron emission tomography (PET) and its impact on therapeutic decision-making in patients with suspected progressive supranuclear palsy (PSP).
Background: PSP presents significant diagnostic challenges due to its phenotypic heterogeneity and symptomatic overlap with other neurodegenerative diseases. PET imaging with florzolotau (18F), a second-generation tau tracer, enables visualization of tau deposits in vivo, but its role in real-world clinical practice remains unclear.
Method: We retrospectively recruited 848 patients with suspected PSP, including 417 with longitudinal follow-up (≥1 year) from movement disorders clinic at Huashan Hospital, Fudan University. Florzolotau (18F) PET images were visually classified as PSP-like and non-PSP-like by neuroradiologists blinded to clinical data. The diagnostic performance of florzolotau (18F) PET visual reading, as well as its impact on diagnostic revision, clinician-rated diagnostic confidence, and medication adjustment, was analyzed.
Results: Florzolotau (18F) PET demonstrated high diagnostic accuracy for PSP, with a sensitivity of 81.2% and a specificity of 96.7%. Integrating florzolotau (18F) PET findings into standard diagnostic work-up led to diagnostic revisions in 31.7% patients. A PSP-like pattern increased clinician-rated diagnostic confidence by 15% (p<0.001) and resulted in more prescriptions of motor symptom medications. Conversely, a non-PSP-like pattern decreased the perceived probability of PSP by 30% (p<0.001).
Conclusion: This large-scale real-world study highlights the substantial clinical utility of florzolotau (18F) PET in enhancing diagnostic accuracy and optimizing therapeutic strategies for patients with suspected PSP, supporting its integration into routine clinical practice.
To cite this abstract in AMA style:
KW. Chan, XY. Li, JY. Lu, C. Zuo, J. Wang, FT. Liu. Role of florzolotau (18F) positron emission tomography in the diagnosis and clinical management of progressive supranuclear palsy: a real-world study [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/role-of-florzolotau-18f-positron-emission-tomography-in-the-diagnosis-and-clinical-management-of-progressive-supranuclear-palsy-a-real-world-study/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/role-of-florzolotau-18f-positron-emission-tomography-in-the-diagnosis-and-clinical-management-of-progressive-supranuclear-palsy-a-real-world-study/